AstraZeneca made its debut at the 8th CIIE and announced an expansion of its manufacturing footprint in China.

On November 5th, as a "perfect attendance student" who has participated in the past eight years, multinational pharmaceutical company AstraZeneca made its debut at the 8th China International Import Expo, announcing the expansion of its production layout in China and the latest achievements in sustainable development, as well as showcasing a variety of innovative drugs. On the first day of the expo, AstraZeneca signed a cooperation agreement with the Management Committee of Qingdao High-tech Industrial Development Zone, announcing an additional investment of approximately $136 million to expand the production capacity of its Qingdao supply base. This expansion will further enhance the production capacity of AstraZeneca's inhalable aerosols to better meet the treatment needs of patients with respiratory diseases such as asthma and COPD. At the same time, the Qingdao base project also utilizes energy-saving technologies to achieve near-zero carbon operation. At this expo, AstraZeneca also showcased for the first time two innovative oncology drugs that were approved in China this year: Calquence and Lynparza. Additionally, several innovative therapies in new disease areas were also highlighted at the booth.